Granted Patent
B2
US 8,841,252 · App. 12/575,886 · Granted Sep 23, 2014
Pharmaceutical formulation
Inventors:
Søren Bjørn (Lyngby, DK); Hans Holmegaard Sørensen (Virum, DK); Peter Langballe (Charlottenlund, DK); Silke Møller Larsen (Charlottenlund, DK); Kristen Ebbehøj (Nærum, DK); Birthe Lykkegaard Hansen (Værløse, DK)
Assignee:
Novo Nordisk Health Care AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.
Claims (2)
1. An aqueous pharmaceutical formulation comprising a) about 1 mg/ml to about 15 mg/ml of human growth hormone (hGH), b) histidine in an amount of about 0.05-about 0.5 mg per mg hGH, c) Poloxamer 188 in an amount of about 0.1-about 2 mg per mg hGH, d) mannitol in an isotonicity conferring amount, and e) phenol in an amount that confers a preservative effect, wherein the formulation has a pH 6.0-6.2, and wherein the hGH is dissolved in said formulation.
2. The formulation of claim 1 , wherein the formulation has a pH of about 6.1.
Assignments (1)
CHANGE OF ADDRESS
Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0226 →
Priority Claims (1)
DK 0490/96
· Apr 24, 1996
· national
Continuity (5)
Provisional Application
60028620
· Aug 28, 1996